IOB - Delayed Quote SEK

BioArctic AB (publ) (0RV2.IL)

185.45

+9.45

+(5.37%)

At close: April 23 at 5:10:30 PM GMT+1

High Growth Tech Stocks To Watch In Europe April 2025

As European markets grapple with the fallout from higher-than-expected U.S. trade tariffs, which have led to significant declines in major indices like the STOXX Europe 600 and Germany's DAX, investors are keenly observing how these developments might impact high-growth tech stocks in the region. In such volatile conditions, a good stock is often characterized by its ability to demonstrate resilience through innovation and adaptability while maintaining strong fundamentals amidst broader...

Simply Wall St. 14 days ago

CRAYF

HMNTY

BRCTF
The European Commission refers lecanemab decision to Appeal Committee

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that the European Commission (EC) has decided to refer the marketing authorisation approval decision of lecanemab in the EU to the Appeal Committee.

PR Newswire 22 days ago

BRCTF
3 European Growth Stocks With Insider Ownership Seeing Up To 52% Earnings Growth

As European markets experience a mix of modest gains and losses, with the pan-European STOXX Europe 600 Index rising slightly amid hopes for increased government spending, investors are navigating a landscape marked by trade-related uncertainties and inflation concerns. In this environment, stocks with high insider ownership can offer an appealing level of confidence, as insiders often have unique insights into their companies' potential for growth and resilience against economic headwinds.

Simply Wall St. 27 days ago

PHMMF

FBGBY

FBGGF
BioArctic receives Orphan Drug Designation for exidavnemab the US

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the US FDA Office of Orphan Products Development (OOPD) has granted orphan drug designation (ODD) to exidavnemab for the treatment of Multiple System Atrophy (MSA), providing incentives for the development of treatments for rare diseases with a high medical need.

PR Newswire last month

BIOA

BRCTF
Exploring High Growth Tech Stocks In Europe March 2025

Amidst a backdrop of global economic uncertainty, the European market has shown resilience with mixed returns across major stock indexes, as the pan-European STOXX Europe 600 Index ended slightly lower following ten weeks of gains. This environment highlights the importance of identifying tech stocks that demonstrate strong growth potential and adaptability to changing market conditions, making them valuable considerations for investors exploring high-growth opportunities in Europe's...

Simply Wall St. last month

CRAYF

BRCTF

HMNTY
The Committee for Medicinal Products for Human Use (CHMP) reaffirms positive opinion for Lecanemab in early Alzheimer's disease in the EU

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has reaffirmed its positive opinion for the anti-Aβ monoclonal antibody lecanemab (Leqembi®), adopted in November 2024. Following CHMP's reaffirmation, after having considered the additional information requested by the European Commission (EC), the EC will resume the decision-making process for lecanemab's marketing

PR Newswire last month

BRCTF
High Insider Owned Growth Stocks With Earnings Up To 69%

In the midst of geopolitical tensions and shifting consumer spending patterns, global markets have experienced a volatile week, with major U.S. indexes seeing early gains erased by sharp losses later on. As investors navigate these uncertainties, growth companies with high insider ownership can be particularly appealing due to their potential alignment of interests between company insiders and shareholders, which may provide an added layer of confidence in turbulent times.

Simply Wall St. last month

BRCTF

AGLFF
Exploring Three High Growth Tech Stocks For Future Potential

As global markets grapple with trade uncertainties and mixed economic signals, with the S&P 500 showing resilience despite tariff concerns, investors are keenly observing sectors that can weather such volatility. In this context, high-growth tech stocks stand out for their potential to capitalize on innovation and adaptability, making them compelling considerations in today's dynamic market landscape.

Simply Wall St. 2 months ago

PBTDF

CCET-F.BK

CCET-R.BK
Tikehau Capital And 2 More Stocks That May Be Priced Below Their Estimated Worth

As global markets navigate a landscape marked by political developments and economic shifts, U.S. stocks have surged to record highs, fueled by optimism over trade policies and advancements in artificial intelligence. Amidst this buoyant market environment, identifying stocks that may be undervalued can offer potential opportunities for investors seeking to capitalize on discrepancies between market price and intrinsic value.

Simply Wall St. 2 months ago

BRCTF

TKKHF
3 Growth Companies Insiders Own With Earnings Growth Up To 51%

As global markets continue to react to political developments and economic indicators, U.S. stocks have been marching toward record highs, buoyed by optimism around softer tariffs and artificial intelligence investments. In this environment of cautious optimism, growth companies with high insider ownership can offer intriguing opportunities for investors, as they often signal confidence in the company's future prospects and alignment between management and shareholders' interests.

Simply Wall St. 2 months ago

HMNKF

BRCTF
FDA approves IV maintenance dosing of Leqembi® (lecanemab-irmb) for the treatment of early Alzheimer's Disease in the US

BioArctic AB (publ) (NASDAQ STOCKHOLM: BIOA B) today announced that the U.S. Food and Drug Administration (FDA) has approved BioArctic's partner Eisai's Supplemental Biologics License Application (sBLA) for Leqembi as a once every four weeks intravenous (IV) maintenance dosing. Leqembi is indicated for the treatment of Alzheimer's disease in patients with mild cognitive impairment (MCI) or mild dementia stage of disease in the U.S. (early Alzheimer's disease). This approval means that patients w

PR Newswire 2 months ago

BRCTF
FDA accepts Biologics License Application for subcutaneous maintenance dosing of Leqembi® (lecanemab-irmb) in the US

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that the U.S. Food and Drug Administration (FDA) has accepted BioArctic's partner Eisai's Biologics License Application (BLA) for Leqembi subcutaneous autoinjector (SC-AI) for weekly maintenance dosingLeqembi is indicated for the treatment of Alzheimer's disease (AD) in patients with Mild Cognitive Impairment (MCI) or mild dementia stage of disease (collectively referred to as early AD). Leqembi is the only FDA-approved anti-amyloid

PR Newswire 3 months ago

BRCTF
High Growth Tech Stocks To Watch In January 2025

As we enter January 2025, global markets have shown mixed performances with the U.S. stock indices closing out a strong year despite recent fluctuations, while economic indicators such as the Chicago PMI and GDP forecasts suggest caution amid contracting manufacturing activity and revised growth expectations. In this context of varied market sentiment, identifying promising high-growth tech stocks involves focusing on companies that demonstrate resilience and adaptability in navigating...

Simply Wall St. 3 months ago

BRCTF

HMNTY
Exploring Undervalued Small Caps With Insider Action In December 2024

As global markets navigate a period of economic uncertainty, small-cap stocks have faced notable challenges, with the Russell 2000 Index underperforming larger counterparts like the S&P 500. Amidst this backdrop, investors are increasingly focused on identifying opportunities within undervalued small-cap companies that may benefit from insider action. In such an environment, a good stock often exhibits resilience and potential for growth despite broader market headwinds, making it crucial to...

Simply Wall St. 4 months ago

BRCTF

2487.HK

TRE.OL
Top Growth Stocks With Insider Backing In December 2024

As global markets navigate a period of mixed performances, with the Nasdaq Composite reaching new heights while other indices face declines, investors are keenly observing the Federal Reserve's anticipated rate cut. In this environment, growth stocks with substantial insider ownership can be particularly appealing as they often signal confidence from those closest to the company's operations and potential.

Simply Wall St. 4 months ago

BRCTF
3 Stocks That May Be Trading Below Their Estimated Intrinsic Value

As global markets navigate a period of economic adjustments and interest rate shifts, investors are keeping a close eye on the Federal Reserve's upcoming decisions and their potential impact on market dynamics. Amidst these fluctuations, identifying stocks that may be trading below their estimated intrinsic value can offer opportunities for long-term growth, especially when broader indices face mixed performance. A good stock in this context is one that demonstrates strong fundamentals and...

Simply Wall St. 4 months ago

BRCTF
High Growth Tech Stocks To Watch This December 2024

As global markets navigate a mixed landscape, with major U.S. indexes like the S&P 500 and Nasdaq hitting record highs while small-cap indices such as the Russell 2000 face declines, investors are keenly observing how growth stocks are outperforming their value counterparts by a significant margin. In this environment, identifying high-growth tech stocks involves looking for companies that demonstrate strong innovation potential and resilience amid economic shifts, making them compelling to...

Simply Wall St. 4 months ago

SOTDF

SOTDY

BRCTF
3 Undervalued Small Caps With Insider Buying Across Global Markets

As global markets navigate the uncertainties surrounding the incoming Trump administration and fluctuating economic indicators, small-cap stocks have experienced varied performance, with indices like the S&P 600 reflecting these dynamics. Amid this backdrop, investors often look for opportunities in undervalued small-cap companies that demonstrate potential resilience through insider buying, suggesting confidence in their future prospects.

Simply Wall St. 5 months ago

BRCTF

FEU.XPHS
Three Stocks Estimated To Be Undervalued In November 2024

As global markets navigate the uncertainties of the incoming Trump administration and fluctuating interest rate expectations, investors are keenly observing sector-specific impacts such as deregulation in financials and energy, alongside challenges faced by healthcare and electric vehicle sectors. In this environment, identifying undervalued stocks becomes crucial; these are companies whose current market prices may not fully reflect their intrinsic value or future potential amidst shifting...

Simply Wall St. 5 months ago

CNSWF

BRCTF
CHMP issues positive recommendation for approval of lecanemab in the EU

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announces that EMA's Committee for Medicinal Products for Human Use (CHMP) has issued a positive recommendation regarding BioArctic's partner Eisai's marketing authorization application (MAA) for lecanemab as treatment of Alzheimer's disease. The recommendation applies to the treatment of early Alzheimer's disease in adult patients that are apolipoprotein E ε4 (ApoE ε4) heterozygotes or non-carriers.

PR Newswire 5 months ago

BRCTF

Performance Overview

Return	0RV2.IL	OMX Stockholm 30 Index (^OMX)
YTD	-7.67%	-3.66%
1-Year	-1.51%	-6.05%
3-Year	+126.02%	+14.20%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

BioArctic AB (publ) (0RV2.IL)

High Growth Tech Stocks To Watch In Europe April 2025

The European Commission refers lecanemab decision to Appeal Committee

3 European Growth Stocks With Insider Ownership Seeing Up To 52% Earnings Growth

BioArctic receives Orphan Drug Designation for exidavnemab the US

Exploring High Growth Tech Stocks In Europe March 2025

The Committee for Medicinal Products for Human Use (CHMP) reaffirms positive opinion for Lecanemab in early Alzheimer's disease in the EU

High Insider Owned Growth Stocks With Earnings Up To 69%

Exploring Three High Growth Tech Stocks For Future Potential

Tikehau Capital And 2 More Stocks That May Be Priced Below Their Estimated Worth

3 Growth Companies Insiders Own With Earnings Growth Up To 51%

FDA approves IV maintenance dosing of Leqembi® (lecanemab-irmb) for the treatment of early Alzheimer's Disease in the US

FDA accepts Biologics License Application for subcutaneous maintenance dosing of Leqembi® (lecanemab-irmb) in the US

High Growth Tech Stocks To Watch In January 2025

Exploring Undervalued Small Caps With Insider Action In December 2024

Top Growth Stocks With Insider Backing In December 2024

3 Stocks That May Be Trading Below Their Estimated Intrinsic Value

High Growth Tech Stocks To Watch This December 2024

3 Undervalued Small Caps With Insider Buying Across Global Markets

Three Stocks Estimated To Be Undervalued In November 2024

CHMP issues positive recommendation for approval of lecanemab in the EU

Performance Overview